AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39399770
Drug: Preoperative subacromial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative subacromial injection of bupivacaine
Trial: 39400005
Drug: Comprehensive remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive remote monitoring (RM) including a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias
Trial: 39400005
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily remote monitoring (control group)
Trial: 39400265
Drug: Herbal formulation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formulation, details on dosage and duration not available
Trial: 39400653
Drug: Aromatherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy group (inhaled Lavender essential oil)
Trial: 39401332
Drug: Intranasal transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal transplantation of ProtheraCytes
Trial: 39401503
Drug: EP-104IAR (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-104IAR (25 mg intra-articular injection)
Trial: 39401504
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (ferrous sulphate 12.5 mg for 6-23 months; 30.0 mg for 24 months and older)
Trial: 39402027
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Trial: 39402027
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Trial: 39402032
Drug: Tebentafusp treatment
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tebentafusp treatment
Trial: 39402448
Drug: IV difelikefalin
RxNorm normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV difelikefalin (3.0 mcg/kg) in NDD subjects with mild renal impairment
Trial: 39402448
Drug: IV difelikefalin
RxNorm normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV difelikefalin (3.0 mcg/kg) in NDD subjects with moderate or severe renal impairment
Trial: 39402448
Drug: IV difelikefalin
RxNorm normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV difelikefalin (0.5, 1.0, or 2.5 mcg/kg) in ESRD subjects undergoing HD
Trial: 39402517
Drug: PE+ therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE+ therapy
Trial: 39402688
Drug: Patient intervention
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient intervention including detection of elevated blood pressure, educational materials, lifestyle modification advice, and medication where needed.
Trial: 39403266
Drug: 20% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% human serum albumin solution injected via the artery immediately after successful reperfusion (maximum dose 0.60 g/kg)
Trial: 39403266
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment alone (ET cohort)
Trial: 39403561
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of BNT162b2 vaccine
Trial: 39403626
Drug: Eftilagimod alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eftilagimod alpha (30 mg subcutaneously every 2 weeks for eight 3-week cycles and then every 3 weeks for up to 54 weeks) plus Pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks)
Trial: 39403781
Drug: Topical therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy, methotrexate, adalimumab, secukinumab, or guselkumab (effective treatment achieving PASI 90)
Trial: 39404994
Drug: Eblasakimab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eblasakimab 400 mg
Trial: 39404994
Drug: Eblasakimab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eblasakimab 600 mg
Trial: 39405373
Drug: FDA-approved new-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT
Trial: 39405605
Drug: CIETAI combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIETAI combined with PD-1 inhibitor tislelizumab plus oxaliplatin, followed by standard concomitant chemoradiotherapy (capecitabine and 50.4 Gy radiation). Intravenous tislelizumab was administered for an additional two cycles.
Trial: 39405911
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) + Metformin (MET)
Trial: 39405978
Drug: Spermidine trihydrochloride
RxNorm normalized name: spermidine
DrugBank: Spermidine (DB03566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermidine trihydrochloride supplement at 40 mg/day
Trial: 39406392
Drug: Postoperative iCav
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative iCav NIVO (1-5-10 mg)
Trial: 39406392
Drug: Historical pooled
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical pooled cohort of Belgian rHGG patients treated with anti-VEGF therapies
Trial: 39406449
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term intensive insulin therapy (SIIT) followed by linagliptin 5 mg/day for 48 weeks
Trial: 39406449
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term intensive insulin therapy (SIIT) followed by metformin 1000 mg/day for 48 weeks
Trial: 39406449
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term intensive insulin therapy (SIIT) followed by combination linagliptin plus metformin for 48 weeks
Trial: 39406449
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term intensive insulin therapy (SIIT) followed by lifestyle modification alone for 48 weeks (control)
Trial: 39407315
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (MgSO4) iontophoresis plus conventional physical therapy program
Trial: 39407315
Drug: High-power pain-threshold
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-power pain-threshold ultrasound (HPPT-US) plus conventional therapy
Trial: 39407325
Drug: mannitol-potentiated low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mannitol-potentiated low-dose amikacin
Trial: 39407325
Drug: ceftriaxone or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftriaxone or amikacin standard dose
Trial: 39407334
Drug: Treat-to-target-driven fixed
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target-driven fixed dose retreatment strategy (usual care group) - retreated with fixed rituximab doses (1 × 1000 mg IV) in case of loss of disease control (DAS28-CRP ≥ 3.2)
Trial: 39407334
Drug: Fixed interval
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed interval disease-activity guided dose optimisation strategy (experimental group) - 24-weekly rituximab treatment with tapering doses: 1 × 1000 mg IV (maximal dose), 1 × 500 mg IV, and 1 × 200 mg IV (minimal dose)
Trial: 39407334
Drug: Fixed interval
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed interval disease-activity guided dose optimisation strategy (experimental group)
Trial: 39407334
Drug: Treat-to-target-driven fixed
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target-driven fixed dose retreatment strategy (usual care group)
Trial: 39407366
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy (control group A)
Trial: 39408354
Drug: 2'-Fucosyllactose (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2'-Fucosyllactose (3 g/d)
Trial: 39408601
Drug: Taldefgrobep alfa
RxNorm normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taldefgrobep alfa as an adjunct to SMN upregulators
Trial: 39410716
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements (T3)
Trial: 39410716
Drug: Magnesium supplements
RxNorm normalized name: Magnesium supplements, alimentary tract and metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplements (T2)
Trial: 39410716
Drug: Both magnesium
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both magnesium and potassium supplements (T4)
Trial: 39411383
Drug: Morphine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.05 mg/kg; i.v.) + oral pramipexole (0.25 mg)
Trial: 39411383
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg; i.v.) + oral placebo
Trial: 39411812
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg plus carboplatin-paclitaxel (four to six cycles) followed by pembrolizumab 400 mg (six cycles)
Trial: 39412509
Drug: Subcutaneous semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous semaglutide 2.4 mg
Trial: 39412619
Drug: Controlled Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled Administration Device (CAD)
Trial: 39412628
Drug: Triptorelin pamoate
RxNorm normalized name: Triptorelin Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin pamoate 22.5 mg (day 1 and month 6)
Trial: 39412860
Drug: Multidisciplinary home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary home-based rehabilitation program (32 sessions for physical therapy, 8 sessions for occupational therapy, 4 sessions for nutrition, 8 sessions for psychology, and 4 sessions for nursing and podiatry over 4 months)
Trial: 39413050
Drug: Super-oxidized solution
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super-oxidized solution
Trial: 39413735
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m²) plus toripalimab
Trial: 39414268
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) provided by regular mental health clinics
Trial: 39414276
Drug: Standardised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised treatment including LLN dissection (LLND) after neoadjuvant treatment and TME surgery.
Trial: 39414276
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment by trained radiation oncologists followed by TME surgery.
Trial: 39414276
Drug: Standardised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised treatment including LLND.
Trial: 39414279
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) including omeprazole, esomeprazole, and pantoprazole
Trial: 39414294
Drug: High-load strength
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-load strength training (2 weekly sessions for 12 weeks)
Trial: 39414341
Drug: Weekly WhatsApp
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly WhatsApp messages on healthy behaviours (Control)
Trial: 39414418
Drug: Once-weekly efanesoctocog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Arm A)
Trial: 39414418
Drug: On-demand efanesoctocog
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand efanesoctocog alfa 50 IU/kg for 26 weeks followed by 26 weeks once-weekly prophylaxis (50 IU/kg; Arm B)
Trial: 39414418
Drug: Pre-study treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-study treatment
Trial: 39414987
Drug: JNJ-42165279 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42165279 (25 mg, twice-daily)
Trial: 39415283
Drug: 12-week structured
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week structured physical activity programme supervised by a sport medicine physician, preceded by three psychoeducation sessions on healthy eating habits.
Trial: 39415344
Drug: Lotiglipron 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotiglipron 80 mg
Trial: 39415344
Drug: Lotiglipron 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotiglipron 200 mg (five-step titration)
Trial: 39415650
Drug: Adjunctive brexpiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brexpiprazole (2–3 mg/day)
Trial: 39415650
Drug: Adjunctive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive placebo (brexpiprazole withdrawal)
Trial: 39415900
Drug: MP0250 in
RxNorm normalized name: Designed ankyrin repeat protein (MP0250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP0250 in combination with bortezomib and dexamethasone
Trial: 39415923
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy (AT-E)
Trial: 39415930
Drug: Venetoclax (VEN)
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax (VEN) at doses of 400, 600, or 800 mg combined with liposomal vincristine (L-VCR) at 2.25 mg/m weekly
Trial: 39415930
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VEN and L-VCR
Trial: 39416174
Drug: ADCT-701, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC)
Trial: 39416950
Drug: Mini-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-dose dexmedetomidine (median 0.02 μg/kg/h)
Trial: 39416990
Drug: Quadrivalent Recombinant
RxNorm normalized name: INFLUENZA VACCINE,QUADRIVALENT RECOMBINANT (PF),SYRINGE,0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent Recombinant Influenza Vaccine (RIV)
Trial: 39416990
Drug: Standard-Dose Inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Inactivated Influenza Vaccine (SD IIV)
Trial: 39417152
Drug: Daily 2
RxNorm normalized name: CVS Oil-Free Daily 2% Acne Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 2 mg mometasone irrigations for 2 months in an optimized position as determined by a patient-specific 3D printed irrigation model (MG)
Trial: 39417152
Drug: Daily 2
RxNorm normalized name: CVS Oil-Free Daily 2% Acne Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 2 mg mometasone irrigations for 2 months with a head tilt of 90° to the side with fluid entering the lower nostril (BG)
Trial: 39417152
Drug: Daily 2
RxNorm normalized name: CVS Oil-Free Daily 2% Acne Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 2 mg mometasone irrigations for 2 months with standard head-forward and natural side-tilt position (CG)
Trial: 39417218
Drug: Reduced 1+1
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced 1+1 PCV dosing schedule
Trial: 39418029
Drug: LEN-IE (lenvatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEN-IE (lenvatinib 14 mg/m2 orally once daily + ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Trial: 39418029
Drug: IE (ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IE (ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Trial: 39418340
Drug: Socazolimab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w
Trial: 39418460
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure (PE) therapy plus sertraline
Trial: 39418644
Drug: CPX-351 plus
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 plus venetoclax (CPX-351 30 units/m2: daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2; venetoclax 400 mg)
Trial: 39418883
Drug: Lapatinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib + Trastuzumab (L + T)
Trial: 39418883
Drug: Trastuzumab followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab followed by Lapatinib (T→L)
Trial: 39419054
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with chemoradiotherapy
Trial: 39419061
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2) followed by adjuvant treatment.
Trial: 39419061
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2).
Trial: 39419061
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment following neoadjuvant treatment.
Trial: 39419348
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 mg/kg for TOF count ≥1 and 4 mg/kg for TOF count = 0)
Trial: 39419615
Drug: Internet-delivered guided
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered guided self-help tinnitus treatment based on ACT combined with tailored sound therapy
Trial: 39419615
Drug: Tailored sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored sound therapy alone
Trial: 39420338
Drug: BDP/FF/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/G
Trial: 39420468
Drug: Angiotensin receptor-neprilysin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor-neprilysin inhibitor (ARNI)
Trial: 39420468
Drug: Angiotensin receptor-neprilysin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor-neprilysin inhibitor (ARNI) with PDC ≥ 80%
Trial: 39421567
Drug: MY-Skills intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MY-Skills intervention (yoga and self-management education), offered twice a week for eight weeks, each session lasting two hours.
Trial: 39421612
Drug: Cholesfytol NG
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesfytol NG (1,000 mg Amla fruit and 50 mg Olive fruit standardized extracts)
Trial: 39422261
Drug: CV0501 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV0501 12 μg dose
Trial: 39422261
Drug: CV0501 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV0501 3 or 6 μg dose
Trial: 39422598
Drug: Fianlimab +
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab + cemiplimab (1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks)
Trial: 39422598
Drug: Fianlimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab monotherapy (exact dosage not specified)
Trial: 39422598
Drug: Transition from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition from fianlimab monotherapy to combination therapy
Trial: 39422598
Drug: Fianlimab pharmacokinetics
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab pharmacokinetics
Trial: 39422598
Drug: Fianlimab 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab 1,600 mg Q3W (20 mg/kg in an 80-kg individual)
Trial: 39422604
Drug: FAP-IL2v (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAP-IL2v (10 mg, QW/Q2W) in combination with cetuximab (500 mg/m2, Q2W)
Trial: 39422741
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m2 administered as a single dose after tumor removal.
Trial: 39422764
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus low-dose bevacizumab
Trial: 39422837
Drug: 0.1% loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% loading dose for 6 months followed by 0.01% for 18 months
Trial: 39422960
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) gene therapy